磷酸西格列汀为DPP-4抑制剂，临床上主要用于改善2型糖尿病患者的血糖控制。本次国药威奇达的磷 酸西格列汀原料药获得《化学原料药上市申请批准通知书》，表明该原料药符合国内药品注册的有关规 定要求，可以在国内市场进行销售，将进一步丰富公司特色专科原料药产品群。 国药现代(600420.SH)发布公告，近日，公司全资子公司国药集团威奇达药业有限公司(简称国药威奇达) 收到国家药品监督管理局关于原料药磷酸西格列汀的《化学原料药上市申请批准通知书》。 ...

格隆汇10月10日丨国药现代(600420.SH)公布，公司全资子公司国药集团威奇达药业有限公司(称国药威 奇达)收到国家药品监督管理局关于原料药磷酸西格列汀的《化学原料药上市申请批准通知书》。磷酸 西格列汀为DPP-4抑制剂，临床上主要用于改善2型糖尿病患者的血糖控制。 ...

智通财经APP讯，国药现代(600420.SH)发布公告，近日，公司全资子公司国药集团威奇达药业有限公 司(简称国药威奇达)收到国家药品监督管理局关于原料药磷酸西格列汀的《化学原料药上市申请批准通 知书》。 磷酸西格列汀为DPP-4抑制剂，临床上主要用于改善2型糖尿病患者的血糖控制。本次国药威奇达的磷 酸西格列汀原料药获得《化学原料药上市申请批准通知书》，表明该原料药符合国内药品注册的有关规 定要求，可以在国内市场进行销售，将进一步丰富公司特色专科原料药产品群。 ...

【国药现代：全资子公司国药威奇达收到磷酸西格列汀化学原料药上市申请批准通知书】智通财经10月 10日电，国药现代(600420.SH)公告称，公司全资子公司国药威奇达收到国家药品监督管理局关于原料 药磷酸西格列汀的《化学原料药上市申请批准通知书》。磷酸西格列汀为DPP-4抑制剂，临床上主要用 于改善2型糖尿病患者的血糖控制。国药威奇达用于开展磷酸西格列汀原料药累计研发投入约529万元。 转自：智通财经 ...

人民财讯10月10日电，国药现代(600420)10月10日公告，全资子公司国药威奇达收到国家药品监督管理 局关于原料药磷酸西格列汀的《化学原料药上市申请批准通知书》。磷酸西格列汀为DPP-4抑制剂，临 床上主要用于改善2型糖尿病患者的血糖控制。 转自：证券时报 ...

Group 1: Company Overview and Market Position - The company is a leading player in the nitroimidazole antibiotic sector, particularly known for its metronidazole raw materials, with the longest industrial chain and the most product varieties globally [2][3] - The main products include metronidazole and its derivatives, with the largest global production capacity and market share, recognized for product quality and cost competitiveness [2][3] Group 2: Performance and Challenges - In 2024, the company faced a significant decline in performance, primarily due to the lithium hexafluorophosphate and metronidazole businesses, with a notable drop in sales prices despite increased sales volume [3][4] - The lithium battery materials sector experienced intensified competition, leading to lower sales prices for lithium hexafluorophosphate, which adversely affected profitability [3][4] - The decline in metronidazole profitability was attributed to increased competition and a decrease in product unit prices, which fell more than the reduction in unit costs [3][4] Group 3: Strategic Responses - The company has implemented a multi-faceted strategy to address current challenges, including cost optimization through production line upgrades and supply chain management [3][4] - Increased investment in research and development to accelerate product technology upgrades and new product development is a key focus [3][4] - Efforts to expand into high-margin product markets are underway to enhance overall profitability [3][4] Group 4: Financial Health and Future Outlook - The company maintains a healthy cash flow and robust financial structure, ensuring sufficient reserves for future operations and investment plans [4] - There are no current risks of delisting as per the Shenzhen Stock Exchange regulations [4] - The company has received approvals for new drug applications, including for sitagliptin phosphate and celecoxib, indicating ongoing product development [4]